Anteris Technologies Global (NASDAQ:AVR – Get Free Report) is one of 142 public companies in the “MED INSTRUMENTS” industry, but how does it weigh in compared to its competitors? We will compare Anteris Technologies Global to related businesses based on the strength of its institutional ownership, risk, valuation, dividends, analyst recommendations, profitability and earnings.
Profitability
This table compares Anteris Technologies Global and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Anteris Technologies Global | N/A | N/A | N/A |
| Anteris Technologies Global Competitors | -182.03% | -90.29% | -20.56% |
Earnings and Valuation
This table compares Anteris Technologies Global and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Anteris Technologies Global | $2.70 million | -$76.29 million | -3.27 |
| Anteris Technologies Global Competitors | $1.75 billion | $196.07 million | 5.03 |
Institutional & Insider Ownership
54.1% of shares of all “MED INSTRUMENTS” companies are owned by institutional investors. 4.0% of Anteris Technologies Global shares are owned by company insiders. Comparatively, 14.1% of shares of all “MED INSTRUMENTS” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock is poised for long-term growth.
Analyst Recommendations
This is a summary of recent recommendations and price targets for Anteris Technologies Global and its competitors, as reported by MarketBeat.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Anteris Technologies Global | 1 | 0 | 4 | 0 | 2.60 |
| Anteris Technologies Global Competitors | 1180 | 3807 | 7144 | 267 | 2.52 |
Anteris Technologies Global presently has a consensus target price of $16.50, suggesting a potential upside of 324.16%. As a group, “MED INSTRUMENTS” companies have a potential upside of 18.77%. Given Anteris Technologies Global’s stronger consensus rating and higher possible upside, equities analysts plainly believe Anteris Technologies Global is more favorable than its competitors.
Anteris Technologies Global Company Profile
Anteris Technologies Global Corp. engages in the development and commercialization of medical devices for heart diseases. The company was founded in 1999 and is headquartered in Eagan, MN.
Receive News & Ratings for Anteris Technologies Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anteris Technologies Global and related companies with MarketBeat.com's FREE daily email newsletter.
